January 20, 2019

January 18, 2019

Subscribe to Latest Legal News and Analysis

January 17, 2019

Subscribe to Latest Legal News and Analysis

UK’s Bioeconomy Policy In Years To Come

On December 5, 2018, the United Kingdom (UK) published a policy paper titled “Growing the Bioeconomy, Improving Lives and Strengthening Our Economy: A National Bioeconomy Strategy to 2030.” As the UK strives to double its bioeconomy value by 2030, four main goals are outlined as part of the strategic plan:

  • Capitalize the research, development, and innovation base;
  • Maximize productivity and potential from existing bioeconomy assets;
  • Deliver real, measurable benefits for the UK economy; and
  • Create the right societal and market conditions to allow innovative biobased products and services to thrive.

Emphasizing the need for collaboration, the paper reports that the transformations necessary to achieve these goals will be led by regional and national government agencies, research councils, universities, and industrial leaders. The vision is that in 2030 the UK will be the global leader in developing, manufacturing, using, and exporting biobased solutions. The outlined strategy takes into account the global challenges facing the world right now and how the bioeconomy can play a critical role in addressing them. The intention is for a new government group to be created in support of the strategy and its related activities.

©2019 Bergeson & Campbell, P.C.

TRENDING LEGAL ANALYSIS


About this Author

Lynn Bergeson, Campbell PC, Toxic Substances Control Act Attorney, federal insecticide lawyer, industrial biotechnology legal counsel, Food Drug Administration law
Managing Partner

Owner of Bergeson & Campbell, P.C. (B&C®), Lynn L. Bergeson has earned an international reputation for her deep and expansive understanding of the Toxic Substances Control Act (TSCA), the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), European Union Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), and especially how these regulatory programs pertain to nanotechnology, industrial biotechnology, synthetic biology, and other emerging transformative technologies. Her knowledge of and involvement in the policy...

202-557-3801